{"id":"https://openalex.org/W2003158932","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5083","title":"Breast Cancer Patients with Very High Tumor HER2 Expression Levels Might Not Benefit from Treatment with Trastzumab Plus Chemotherapy: A Retrospective Exploratory Analysis of the FinHer Trial.","display_name":"Breast Cancer Patients with Very High Tumor HER2 Expression Levels Might Not Benefit from Treatment with Trastzumab Plus Chemotherapy: A Retrospective Exploratory Analysis of the FinHer Trial.","publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2003158932","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5083","mag":"2003158932"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.sabcs-09-5083","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5083","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.sabcs-09-5083","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090618504","display_name":"Heikki Joensuu","orcid":"https://orcid.org/0000-0003-0281-2507","observed_orcids":["https://orcid.org/0000-0003-0281-2507"]},"institutions":[{"id":"https://openalex.org/I2800394112","display_name":"Helsinki University Hospital","ror":"https://ror.org/02e8hzf44","country_code":"FI","type":"healthcare","lineage":["https://openalex.org/I2800394112","https://openalex.org/I4210166427"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"H. Joensuu","raw_affiliation_strings":["1Helsinki University Central Hospital, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Helsinki University Central Hospital, Finland","institution_ids":["https://openalex.org/I2800394112"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081802864","display_name":"Jeff Sperinde","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Sperinde","raw_affiliation_strings":["2Monogram Biosciences, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Monogram Biosciences, CA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113633132","display_name":"M. Leinonen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Leinonen","raw_affiliation_strings":["3Pharma, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pharma, Finland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083535676","display_name":"Weidong Huang","orcid":"https://orcid.org/0000-0003-2798-4735","observed_orcids":["https://orcid.org/0000-0003-2798-4735"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Huang","raw_affiliation_strings":["2Monogram Biosciences, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Monogram Biosciences, CA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043601605","display_name":"Jodi Marie Weidler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Weidler","raw_affiliation_strings":["2Monogram Biosciences, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Monogram Biosciences, CA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006874570","display_name":"Petri Bono","orcid":"https://orcid.org/0000-0003-3963-0416","observed_orcids":["https://orcid.org/0000-0003-3963-0416"]},"institutions":[{"id":"https://openalex.org/I2800394112","display_name":"Helsinki University Hospital","ror":"https://ror.org/02e8hzf44","country_code":"FI","type":"healthcare","lineage":["https://openalex.org/I2800394112","https://openalex.org/I4210166427"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"P. Bono","raw_affiliation_strings":["1Helsinki University Central Hospital, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Helsinki University Central Hospital, Finland","institution_ids":["https://openalex.org/I2800394112"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068108014","display_name":"Jorma J Isola","orcid":"https://orcid.org/0000-0002-0849-5939","observed_orcids":["https://orcid.org/0000-0002-0849-5939"]},"institutions":[{"id":"https://openalex.org/I4210126318","display_name":"Tampere University Hospital","ror":"https://ror.org/02hvt5f17","country_code":"FI","type":"healthcare","lineage":["https://openalex.org/I4210126318"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"J. Isola","raw_affiliation_strings":["4Tampere University Hospital, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Tampere University Hospital, Finland","institution_ids":["https://openalex.org/I4210126318"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108588816","display_name":"Pirkko Kellokumpu\u2010Lehtinen","orcid":"https://orcid.org/0000-0002-5557-0911","observed_orcids":["https://orcid.org/0000-0002-5557-0911"]},"institutions":[{"id":"https://openalex.org/I4210126318","display_name":"Tampere University Hospital","ror":"https://ror.org/02hvt5f17","country_code":"FI","type":"healthcare","lineage":["https://openalex.org/I4210126318"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"P. Kellokumpu-Lehtinen","raw_affiliation_strings":["4Tampere University Hospital, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Tampere University Hospital, Finland","institution_ids":["https://openalex.org/I4210126318"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111966562","display_name":"Michael Patrick Bates","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Bates","raw_affiliation_strings":["2Monogram Biosciences, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Monogram Biosciences, CA,","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"69","issue":"24_Supplement","first_page":"5083","last_page":"5083"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-overexpression","display_name":"HER2 overexpression","score":0.8420000076293945},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9739999771118164},{"id":"https://openalex.org/keywords/adjuvant-chemotherapy","display_name":"adjuvant chemotherapy","score":0.8479999899864197},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.6150000095367432},{"id":"https://openalex.org/keywords/treatment-heterogeneity","display_name":"treatment effect heterogeneity","score":0.6600000262260437},{"id":"https://openalex.org/keywords/distant-recurrence","display_name":"distant recurrence","score":0.6589999794960022},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9890000224113464},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.5099999904632568},{"id":"https://openalex.org/keywords/biomarker-cutoff-values","display_name":"biomarker cut-off values","score":0.37400001287460327},{"id":"https://openalex.org/keywords/trastuzumab-resistance","display_name":"trastuzumab resistance","score":0.7149999737739563},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.3869999945163727}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8933950662612915},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8562015295028687},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6932268142700195},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6837239265441895},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6211657524108887},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.5947052836418152},{"id":"https://openalex.org/C121313828","wikidata":"https://www.wikidata.org/wiki/Q17861998","display_name":"CISH","level":5,"score":0.58613121509552},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.47748658061027527},{"id":"https://openalex.org/C2776643354","wikidata":"https://www.wikidata.org/wiki/Q5113886","display_name":"Chromogenic in situ hybridization","level":5,"score":0.4773036241531372},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4650396406650543},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4604855477809906},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45720842480659485},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4551723599433899},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4482274353504181},{"id":"https://openalex.org/C81439078","wikidata":"https://www.wikidata.org/wiki/Q2304142","display_name":"In situ hybridization","level":4,"score":0.10845175385475159},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06932193040847778},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.sabcs-09-5083","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5083","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.sabcs-09-5083","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2161194581","https://openalex.org/W2590091864","https://openalex.org/W2332065349","https://openalex.org/W2597105685","https://openalex.org/W2041442095","https://openalex.org/W2152487358","https://openalex.org/W2588603370","https://openalex.org/W2243661737","https://openalex.org/W1462081572","https://openalex.org/W2056221530"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"FinHer":[2,127],"(NEJM":[3],"2006)":[4],"is":[5,82],"one":[6],"of":[7,40,64,76,130,176,245,324,343,349,357,367,382,390,396,399,405,433],"the":[8,47,91,107,114,126,131,143,242,247,266,270,325,332,352,355,360,394,402,421],"several":[9],"prospective":[10],"randomized":[11,148,346,431],"clinical":[12,17,94,183,219,239,368],"trials":[13,432],"that":[14,29],"show":[15,211],"a":[16,62,206,212,344],"benefit":[18,95,220,285,369],"from":[19,96,122,221,286,335,370,420],"trastuzumab":[20,55,77,97,150,222,251,287,350,376,383,434],"added":[21],"to":[22,61,149,173,189,210,231,253,264,292,384,426],"adjuvant":[23,353],"chemotherapy.":[24],"We":[25],"have":[26],"previously":[27],"reported":[28],"patients":[30,65,123,145,179,358],"with":[31,54,276,304,329,359,417],"metastatic":[32,422],"breast":[33,437],"cancer":[34,72],"who":[35,51,66,146,180],"had":[36,56,67],"very":[37,83,271,277,318],"high":[38,84,272,278,319],"levels":[39,217,244,404],"HER2":[41,70,80,100,177,215,391,400],"protein":[42,101],"expression":[43,102,216],"as":[44,104,197,205],"measured":[45],"by":[46,106,113,135],"HERmark":[48,108,115],"assay":[49,116],"and":[50,69,98,168,193,218,238,256],"were":[52,133,147,171,229,262],"treated":[53],"similar":[57],"time-to-progression":[58],"(TTP)":[59],"compared":[60,328],"group":[63,321],"FISH-negative":[68],"normal":[71],"suggesting":[73],"reduced":[74],"efficacy":[75],"when":[78],"tumor":[79],"content":[81],"(Sperinde,":[85],"ASCO":[86],"2009).":[87],"Here":[88],"we":[89],"investigate":[90],"relationship":[92,213],"between":[93,214,236],"quantitative":[99],"(H2T)":[103],"determined":[105],"assay.Methods:":[109],"H2T":[110,204,237,273,279,305,320,362],"was":[111],"quantitated":[112],"in":[117,125,137,331,351,415,429,435],"899":[118],"formalin-fixed":[119],"paraffin-embedded":[120],"specimens":[121],"enrolled":[124],"trial;":[128],"196":[129],"samples":[132],"HER2-positive":[134,144,326],"chromogenic":[136],"situ":[138],"hybridization":[139],"(CISH).":[140],"Focusing":[141],"on":[142,185],"treatment":[151,159,252,290],"or":[152,393],"control,":[153],"Cox":[154,199],"proportional":[155,200],"hazards":[156,201],"analyses,":[157,167],"sub-population":[158],"effect":[160],"pattern":[161],"plots":[162],"(STEPP":[163],"analyses),":[164],"positional":[165],"scanning":[166,260],"Kaplan-Meier":[169],"analyses":[170,202,228,261],"used":[172],"identify":[174,265],"sub-populations":[175],"over-expressing":[178],"experienced":[181],"different":[182],"outcomes":[184],"trastuzumab.Results:":[186],"Using":[187],"time":[188],"distant":[190],"recurrence":[191],"(TDR)":[192],"overall":[194],"survival":[195],"(OS)":[196],"endpoints,":[198],"treating":[203],"continuous":[207],"variable":[208],"failed":[209],"(HR=1,":[223],"p=ns":[224],"for":[225,233,296,300,311,315],"both).":[226],"STEPP":[227],"performed":[230],"look":[232],"non-linear":[234],"relationships":[235],"outcome.":[240],"At":[241],"highest":[243,361,403],"H2T,":[246],"hazard":[248],"ratio":[249],"comparing":[250],"control":[254],"approached":[255],"exceeded":[257],"1.":[258],"Positional":[259],"conducted":[263],"optimal":[267],"cutoff":[268],"discriminating":[269],"group.":[274],"Patients":[275],"values":[280,306,363],"(>=":[281],"125.9)":[282],"did":[283,308],"not":[284],"plus":[288],"chemotherapy":[289],"relative":[291],"controls":[293],"(HR=1.23,":[294],"p=0.75":[295],"TDR,":[297,312],"HR=1.05,":[298],"p=0.95":[299],"OS),":[301],"while":[302],"those":[303],"<125.9":[307],"(HR=0.52,":[309],"p=0.05":[310],"HR=0.48,":[313],"p=0.1":[314],"OS).":[316],"The":[317],"represented":[322],"13%":[323,356],"population":[327],"16%":[330],"prior":[333,418],"study":[334],"Sperinde":[336],"et":[337],"al.Discussion:":[338],"In":[339],"this":[340],"exploratory":[341],"analysis":[342],"prospectively":[345],"controlled":[347],"trial":[348],"setting,":[354,423],"showed":[364],"no":[365],"evidence":[366],"trastuzumab.":[371],"Potential":[372],"explanations":[373],"include":[374],"insufficient":[375],"dose,":[377],"steric":[378],"hindrance":[379],"preventing":[380],"access":[381],"its":[385],"epitope":[386],"target":[387],"under":[388],"conditions":[389],"over-crowding,":[392],"existence":[395],"trastuzumab-resistant":[397],"forms":[398],"at":[401],"over-expression":[406],"(e.g.":[407],"p95/HER2,":[408],"HER2:HER3":[409],"heterodimers).":[410],"Although":[411],"these":[412],"results":[413],"are":[414],"agreement":[416],"observations":[419],"they":[424],"need":[425],"be":[427],"confirmed":[428],"larger":[430],"early":[436],"cancer.":[438],"Citation":[439],"Information:":[440],"Cancer":[441],"Res":[442],"2009;69(24":[443],"Suppl):Abstract":[444],"nr":[445],"5083.":[446]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}